To help neurologists, clinicians and families understand the current evidence for a new gene therapy for Duchenne muscular dystrophy called delandistrogene moxeparvovec, the American Academy of Neurology (AAN) has issued an Evidence in Focus article, published May 14, 2025, online in Neurology®.
AAN Evidence in Focus articles highlight the strength of the current evidence for new therapies for neurological conditions. Their purpose is not to provide recommendations for practice, but rather…
Continue Reading
News Source: www.sciencedaily.com
Leave a Reply